Literature DB >> 17911385

Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes.

B N Yamaja Setty1, Suhita Gayen Betal.   

Abstract

Phosphatidylserine (PS)-positive erythrocytes adhere to endothelium and subendothelial matrix components. While thrombospondin mediates these inter-actions, it is unknown whether PS-associated erythrocyte-endothelial adhesion occurs in the absence of plasma ligands. Using ionophore-treated PS-expressing control HbAA erythrocytes, we demonstrate that PS-positive erythrocytes adhered to human lung microendothelial cells in the absence of plasma ligands, that this adhesion was enhanced following endothelial activation with IL-1alpha, TNF-alpha, LPS, hypoxia, and heme, and that this adhesive interaction was selective to erythrocyte PS. We next explored whether microendothelial cells express an adhesion receptor that recognizes cell surface-expressed PS (PSR) similar to that expressed on activated macrophages. We demonstrate constitutive expression of both PSR mRNA and protein that were up-regulated in a time-dependent manner following endothelial activation. While minimal PSR expression was noted on unstimulated cells, endothelial activation up-regulated PSR surface expression. In antibody-blocking studies, using PS-positive erythrocytes generated either artificially via ionophore treatment of control erythrocytes or from patients with sickle cell disease, we demonstrate that PSR was functional, supporting PS-mediated erythrocyte adhesion to activated endothelium. Our results demonstrate the existence of a novel functional adhesion receptor for PS on the microendothelium that is up-regulated by such pathologically relevant agonists as hypoxia, cytokines, and heme.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911385      PMCID: PMC2200830          DOI: 10.1182/blood-2007-07-099465

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

1.  A receptor for phosphatidylserine-specific clearance of apoptotic cells.

Authors:  V A Fadok; D L Bratton; D M Rose; A Pearson; R A Ezekewitz; P M Henson
Journal:  Nature       Date:  2000-05-04       Impact factor: 49.962

2.  Sickle cell anemia as an inflammatory disease.

Authors:  O S Platt
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

3.  P-selectin mediates the adhesion of sickle erythrocytes to the endothelium.

Authors:  N M Matsui; L Borsig; S D Rosen; M Yaghmai; A Varki; S H Embury
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

4.  Thrombophilia in sickle cell disease: the red cell connection.

Authors:  B N Setty; A K Rao; M J Stuart
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

5.  Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation.

Authors:  Junette S Mohan; Gregory Yh Lip; Josh Wright; David Bareford; Andrew D Blann
Journal:  Blood Coagul Fibrinolysis       Date:  2005-04       Impact factor: 1.276

6.  Characterization of the phosphatidylserine-exposing subpopulation of sickle cells.

Authors:  K de Jong; S K Larkin; L A Styles; R M Bookchin; F A Kuypers
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

7.  Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium.

Authors:  C Closse; J Dachary-Prigent; M R Boisseau
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

8.  Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion.

Authors:  B N Setty; S Kulkarni; C D Dampier; M J Stuart
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

9.  Integrin-associated protein is an adhesion receptor on sickle red blood cells for immobilized thrombospondin.

Authors:  J E Brittain; K J Mlinar; C S Anderson; E P Orringer; L V Parise
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

10.  Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin.

Authors:  A B Manodori; G A Barabino; B H Lubin; F A Kuypers
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

View more
  28 in total

1.  The rationale for using hydroxycarbamide in the treatment of sickle cell disease" (Haematologica 2011;96:488-491). Reply.

Authors:  Simeon Pollack
Journal:  Haematologica       Date:  2011-06       Impact factor: 9.941

2.  High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy.

Authors:  Jin Gao; Sihan Wang; Zhenjia Wang
Journal:  Biomaterials       Date:  2017-05-03       Impact factor: 12.479

3.  Stored red blood cell susceptibility to in vitro transfusion-associated stress conditions is higher after longer storage and increased by storage in saline-adenine-glucose-mannitol compared to AS-1.

Authors:  Diana Mittag; Amrita Sran; Kasey S Chan; Martin P Boland; Esther Bandala-Sanchez; Olivier Huet; William Xu; Rosemary L Sparrow
Journal:  Transfusion       Date:  2015-05-13       Impact factor: 3.157

Review 4.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

5.  Phosphatidylserine-positive erythrocytes bind to immobilized and soluble thrombospondin-1 via its heparin-binding domain.

Authors:  Suhita Gayen Betal; B N Yamaja Setty
Journal:  Transl Res       Date:  2008-09-04       Impact factor: 7.012

6.  Inflammation in sickle cell disease.

Authors:  Nicola Conran; John D Belcher
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

7.  A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

Authors:  Pedro Cabrales; Jan Scicinski; Tony Reid; Frans Kuypers; Sandra Larkin; Marcel Fens; Arnold Oronsky; Bryan Oronsky
Journal:  Med Oncol       Date:  2016-05-26       Impact factor: 3.064

Review 8.  Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.

Authors:  Gregory J Kato; Mark T Gladwin
Journal:  JAMA       Date:  2008-12-10       Impact factor: 56.272

9.  Intravital Vascular Phototheranostics and Real-Time Circulation Dynamics of Micro- and Nanosized Erythrocyte-Derived Carriers.

Authors:  Wangcun Jia; Joshua M Burns; Betty Villantay; Jack C Tang; Raviraj Vankayala; Ben Lertsakdadet; Bernard Choi; J Stuart Nelson; Bahman Anvari
Journal:  ACS Appl Mater Interfaces       Date:  2019-12-24       Impact factor: 9.229

10.  Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside.

Authors:  Ana Villegas; Fernando A Gonzalez; Leopoldo Llorente; Santiago Redondo
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.